Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | FPR3 | P25089 | 3/20 | 0.40 |
| ▸ | FPR2 | P25090 | 3/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7345915 | 0.95 | PRCP (0.64) | PRCPTDP1EPHX1MAOAMAOB | |
| SCHEMBL13767206 | 0.89 | PRCP (0.56) | PRCPTDP1EPHX1MEN1GAA | |
| SCHEMBL18631769 | 0.83 | PRCP (0.74) | PRCPEPHX1TLR2NAAA | |
| SCHEMBL18631778 | 0.83 | PRCP (0.74) | PRCPEPHX1TLR2NAAA | |
| SCHEMBL15665243 | 0.82 | PRCP (0.61) | PRCPTLR2FPR3FPR2 | |
| SCHEMBL15665421 | 0.82 | PRCP (0.61) | PRCPTLR2FPR3FPR2 | |
| SCHEMBL5898615 | 0.81 | PRCP (0.91) | PRCPEPHX1TLR2NAAA | |
| SCHEMBL5898616 | 0.80 | PRCP (0.89) | PRCPEPHX1TLR2NAAA | |
| SCHEMBL4630085 | 0.79 | SCN9A (0.39) | PRCPEPHX1GAA | |
| SCHEMBL3231149 | 0.79 | PRCP (0.88) | PRCPEPHX1TLR2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263730-B1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | disclosed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | disclosed |
| EP-1263730-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | Applied Research Systems ARS Holding N.V. (AN) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001060798-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-08-23 | — | — | WO | disclosed |
| EP-1125925-A1 | Amine derivatives for the treatment of apoptosis | Applied Research Systems ARS Holding N.V. (AN) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | BAD, BAX, BCL2 | PRCP 1913/4885TDP1 1038/4885EPHX1 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.